Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
3TC may be uniquely effective in combination with AZT due to the interaction of AZT and 3TC resistance mutations. One explanation is that the M184V mutation, which confers resistance to 3TC, suppresses AZT resistance. This benefit of 3TC may not extend to combination therapy with other nucleoside analogs.
Patients are randomized to either a ddI limb or d4T limb, then randomized a second time to one of six treatment arms, as follows: ddI alone, d4T alone, 3TC/AZT (on both ddI and d4T limbs), 3TC/ddI, and 3TC/d4T. Treatment is given for 48 weeks. At study week 24, patients on monotherapy wil...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Concurrent Medication:
- Allowed:
- • PCP prophylaxis.
- Patients must have:
- • HIV infection.
- • CD4 count 200 - 600 cells/mm3.
- • Life expectancy of at least 24 weeks.
- • Consent of parent or guardian if less than 18 years old.
- • Exclusion Criteria
- Co-existing Condition:
- Patients with the following symptoms or conditions are excluded:
- • Unexplained temperature \>= 38.5 C for 7 consecutive days within 30 days prior to study entry.
- PER AMENDMENT 1/25/96:
- • A malignancy that requires systemic chemotherapies other than Kaposi's sarcoma.
- Concurrent Medication:
- Excluded:
- • Concurrent other antiretroviral or immunologic agents.
- • Other experimental therapies.
- • Systemic corticosteroids (except as adjuvant therapy for acute PCP) and other immunosuppressive drugs.
- • Systemic cytotoxic chemotherapy.
- • Induction or maintenance with foscarnet or ganciclovir (oral or IV).
- Patients with the following prior conditions are excluded:
- • History of acute or chronic pancreatitis.
- • History of grade 2 or higher peripheral neuropathy.
- Prior Medication:
- Excluded:
- • Antiretrovirals within 90 days prior to study entry.
- • More than 7 days total lifetime use of any antiretroviral nucleoside.
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Los Angeles, California, United States
Palo Alto, California, United States
San Diego, California, United States
San Jose, California, United States
San Mateo, California, United States
Aurora, Colorado, United States
Miami, Florida, United States
Honolulu, Hawaii, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Indianapolis, Indiana, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Saint Louis, Missouri, United States
Saint Louis, Missouri, United States
Buffalo, New York, United States
New York, New York, United States
New York, New York, United States
Rochester, New York, United States
Chapel Hill, North Carolina, United States
Charlotte, North Carolina, United States
Greensboro, North Carolina, United States
Cleveland, Ohio, United States
Philadelphia, Pennsylvania, United States
Seattle, Washington, United States
San Juan, , Puerto Rico
Chicago, Illinois, United States
Honolulu, Hawaii, United States
Columbus, Ohio, United States
Patients applied
Trial Officials
Kuritzkes D
Study Chair
Johnson V
Study Chair
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials